Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif.
作者信息
Lorvick J, Kral A H, Seal K, Gee L, Edlin B R
机构信息
Urban Health Study, University of California, San Francisco, Box 1304, San Francisco, CA 94143-1304, USA.
出版信息
Am J Public Health. 2001 Jan;91(1):46-7. doi: 10.2105/ajph.91.1.46.
Abstract
摘要
相似文献
1
Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif.
Am J Public Health. 2001 Jan;91(1):46-7. doi: 10.2105/ajph.91.1.46.
2
Effects of duration of injection drug use and age at first injection on HCV among IDU in Kabul, Afghanistan.
J Public Health (Oxf). 2010 Sep;32(3):336-41. doi: 10.1093/pubmed/fdq020. Epub 2010 Apr 26.
3
Re: "Risk of hepatitis C virus among young adult injection drug users who share injection equipment".
Am J Epidemiol. 2003 Feb 15;157(4):376; author reply 376-8. doi: 10.1093/aje/kwf197.
4
Prevalence of hepatitis C infection in injection drug users in Hong Kong.
Hong Kong Med J. 2009 Dec;15 Suppl 8:45-6.
5
Hepatitis C among drug users: déjà vu all over again?
Am J Public Health. 2001 Jan;91(1):21-2. doi: 10.2105/ajph.91.1.21.
6
Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO Study.
Am J Public Health. 2003 Jun;93(6):919-23. doi: 10.2105/ajph.93.6.919.
7
Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco.
Hepatology. 2001 Jul;34(1):180-7. doi: 10.1053/jhep.2001.25759.
8
Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working?
Am J Public Health. 2001 Jan;91(1):38-42. doi: 10.2105/ajph.91.1.38.
9
Detection of multiple hepatitis C virus genotypes in a cohort of injecting drug users.
J Viral Hepat. 2005 May;12(3):322-4. doi: 10.1111/j.1365-2893.2005.00592.x.
10
Hepatitis C infection among men who have sex with men, San Francisco, 2011.
Sex Transm Dis. 2012 Dec;39(12):985-6. doi: 10.1097/OLQ.0b013e3182716e59.
引用本文的文献
1
Prevalence and associated risk factors of current hepatitis C infection among U.S. general population and injection drug users aged 20-59 years: NHANES 2009-2018.
PLoS One. 2024 Aug 26;19(8):e0309345. doi: 10.1371/journal.pone.0309345. eCollection 2024.
2
GRAND PLAN: Safety and Efficacy of Glecaprevir/Pibrentasvir for the Treatment of Hepatitis C Virus Infection Among People Initially Disengaged From Health Care Who Use Drugs-A Systematic Multidisciplinary Approach.
Open Forum Infect Dis. 2024 Mar 5;11(3):ofad638. doi: 10.1093/ofid/ofad638. eCollection 2024 Mar.
3
Machine learning for predicting hepatitis B or C virus infection in diabetic patients.
Sci Rep. 2023 Dec 6;13(1):21518. doi: 10.1038/s41598-023-49046-9.
4
Development of a predictive model for identifying women vulnerable to HIV in Chicago.
BMC Womens Health. 2023 Jun 16;23(1):313. doi: 10.1186/s12905-023-02460-7.
5
Opioid epidemic and liver disease.
JHEP Rep. 2019 Jul 9;1(3):240-255. doi: 10.1016/j.jhepr.2019.06.006. eCollection 2019 Sep.
6
Acceptability of safe drug consumption spaces among people who inject drugs in rural West Virginia.
Harm Reduct J. 2019 Aug 31;16(1):51. doi: 10.1186/s12954-019-0320-8.
7
Potential use of supervised injection services among people who inject drugs in a remote and mid-size Canadian setting.
BMC Public Health. 2019 Mar 8;19(1):284. doi: 10.1186/s12889-019-6606-7.
8
Hepatitis C Treatment in Patients with Drug Addiction Is Effective or Not Effective?
Med Arch. 2018 Nov;72(5):325-329. doi: 10.5455/medarh.2018.72.325-329.
9
No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00958-17. Print 2017 Oct.
10
Acceptability and design preferences of supervised injection services among people who inject drugs in a mid-sized Canadian City.
Harm Reduct J. 2017 Jul 14;14(1):46. doi: 10.1186/s12954-017-0174-x.
本文引用的文献
1
Incentives and accessibility: a pilot study to promote adherence to TB prophylaxis in a high-risk community.
J Urban Health. 1999 Dec;76(4):461-7. doi: 10.1007/BF02351503.
2
Syringe exchange and risk of infection with hepatitis B and C viruses.
Am J Epidemiol. 1999 Feb 1;149(3):203-13. doi: 10.1093/oxfordjournals.aje.a009792.
3
Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study.
BMJ. 1998 Aug 15;317(7156):433-7. doi: 10.1136/bmj.317.7156.433.
4
Prevalence and incidence of hepatitis C virus infection among young adult injection drug users.
J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18 Suppl 1:S11-9. doi: 10.1097/00042560-199802001-00004.
5
Epidemiology of hepatitis C.
Hepatology. 1997 Sep;26(3 Suppl 1):62S-65S. doi: 10.1002/hep.510260711.
6
Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence.
Scand J Infect Dis. 1996;28(1):27-9. doi: 10.3109/00365549609027145.
7
Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin.
AIDS. 1996 Mar;10(3):311-7.
8
Syringe-mediated drug sharing among injecting drug users: patterns, social context and implications for transmission of blood-borne pathogens.
Soc Sci Med. 1996 Mar;42(5):691-703. doi: 10.1016/0277-9536(95)00193-x.
9
Detection of HIV-1 DNA in needle/syringes, paraphernalia, and washes from shooting galleries in Miami: a preliminary laboratory report.
J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Mar 1;11(3):301-6. doi: 10.1097/00042560-199603010-00010.
10
A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam.
Eur J Epidemiol. 1993 May;9(3):255-62. doi: 10.1007/BF00146260.
Zotero 插件